Literature DB >> 12189529

Efficient genetic modification of murine dendritic cells by electroporation with mRNA.

Sonja Van Meirvenne1, Lieven Straetman, Carlo Heirman, Melissa Dullaers, Catherine De Greef, Viggo Van Tendeloo, Kris Thielemans.   

Abstract

Recently, human dendritic cells (DCs) pulsed with mRNA encoding a broad range of tumor antigens have proven to be potent activators of a primary anti-tumor-specific T-cell response in vitro. The aim of this study was to improve the mRNA pulsing of murine DC. Compared to a standard lipofection protocol and passive pulsing, electroporation was, in our hands, the most efficient method. The optimal conditions to electroporate murine bone marrow-derived DCs with mRNA were determined using enhanced green fluorescent protein and a truncated form of the nerve growth factor receptor. We could obtain high transfection efficiencies around 70-80% with a mean fluorescence intensity of 100-200. A maximal expression level was reached 3 hours after electroporation. A clear dose-response effect was seen depending on the amount of mRNA used. Importantly, the electroporation process did not affect the viability nor the allostimulatory capacity or phenotype of the DC. To study the capacity of mRNA-electroporated DCs to present antigen in the context of MHC classes I and II, we made use of chimeric constructs of ovalbumin. The dose-dependent response effect and the duration of presentation were also determined. Together, these results demonstrate that mRNA electroporation is a useful method to generate genetically modified murine DC, which can be used for preclinical studies testing immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12189529     DOI: 10.1038/sj.cgt.7700499

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  36 in total

1.  Gene delivery efficiency in bone marrow-derived dendritic cells: comparison of four methods and optimization for lentivirus transduction.

Authors:  Gong-Bo Li; Guang-Xiu Lu
Journal:  Mol Biotechnol       Date:  2009-07-14       Impact factor: 2.695

Review 2.  Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9.

Authors:  Hong-Xia Zhang; Ying Zhang; Hao Yin
Journal:  Mol Ther       Date:  2019-01-25       Impact factor: 11.454

Review 3.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

Review 4.  In vitro and ex vivo strategies for intracellular delivery.

Authors:  Martin P Stewart; Armon Sharei; Xiaoyun Ding; Gaurav Sahay; Robert Langer; Klavs F Jensen
Journal:  Nature       Date:  2016-10-13       Impact factor: 49.962

5.  Calcein Release from Cells In Vitro via Reversible and Irreversible Electroporation.

Authors:  Violeta Rajeckaitė; Baltramiejus Jakštys; Arnas Rafanavičius; Martynas Maciulevičius; Milda Jakutavičiūtė; Saulius Šatkauskas
Journal:  J Membr Biol       Date:  2017-11-15       Impact factor: 1.843

Review 6.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 7.  Active immunotherapy: current state of the art in vaccine approaches for NHL.

Authors:  M Lia Palomba
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

8.  Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).

Authors:  Sung Hee Yoon; Jin Myung Lee; Sun-Je Woo; Min-Ji Park; Jung-Sun Park; Hye-Sung Kim; Mi-Young Park; Hyun-Jung Sohn; Tai-Gyu Kim
Journal:  J Clin Immunol       Date:  2009-06-11       Impact factor: 8.317

9.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

10.  In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma.

Authors:  W Maes; C Deroose; V Reumers; O Krylyshkina; R Gijsbers; V Baekelandt; J Ceuppens; Z Debyser; S W Van Gool
Journal:  J Neurooncol       Date:  2008-09-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.